Highlights:
Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations
Maria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy
Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair.
During his mandate, Alessandro Chiesi oversaw the Group through a phase of continued international development and governance strengthening, thereby further consolidating Chiesi’s long-term strategy as a research focused biopharmaceutical company and certified B Corp.
“It has been my privilege to serve as Chair during a period of evolution for Chiesi,” said Alessandro Chiesi. “What has remained unchanged is the Group’s firm roots in our clear values, strong sense of responsibility, and long-term vision. On behalf of the Board and personally, I congratulate Maria Paola on her appointment and offer her our collective support. I am honored to assume the Vice Chair role, and I will continue working to support Chiesi in advancing its stated objectives.”
The Board has unanimously appointed Maria Paola Chiesi as Chair, effective immediately. As a member of the Chiesi family and Board, and through her operational roles over the last 30 years, she has played a central role in shaping the Group’s strategic planning and in embedding sustainability as a core driver of business decisions. This appointment also marks an important milestone in the Group’s history, as she becomes the first woman Chair of Chiesi.
“I take on this new role with a deep sense of accountability, and with the aim to reinforce our continuity and commitment to the values that have guided Chiesi through generations,” said Maria Paola Chiesi. “For us, science that cares means pursuing scientific innovation with responsibility for its impact on people, society and the environment. As ever, this principle underpins our identity as a Benefit Corporation and B Corp, and it makes sustainability an integral part of our business model, embedded in how we make decisions and create long-term value for patients, communities and future generations.”
This transition reflects the Board’s intention to maintain stability and coherence in governance, while continuing to align growth, innovation, and sustainability through a long-term, multigenerational perspective.
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet verified standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com
Contacts
Press Info:
Anna Bonisoli Alquati, Head of Global External Communications: mediarelations@chiesi.com
Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com
Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy
-
Chiesi Group Announces New Chair and Vice ChairHighlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and r2026-05-22
-
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared SpeciSinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that i2026-05-22
-
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate inPrecemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM2026-05-22
-
Omdia:到2030年,Amazon、Netflix和Google将占据810亿美元联网电视广告市场的半壁江山根据Omdia的最新研究,全球联网电视(CTV)广告营收将从2025年的440亿美元飙升至2030年的810亿美元,CTV广告营收有望在2030年代超越传统线性电视广告。 Google、A2026-05-22
-
The Estée Lauder Companies与Puig终止关于潜在业务合并的磋商The Estée Lauder Companies重申对“重塑美妆新境”(Beauty Reimagined)战略愿景的信心 2026年3月23日,The Estée Lauder Companies Inc.(NYSE:EL)与Puig确认,双方2026-05-22
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
慧启赣疆 聚势共赢丨慧友酒店集团江西品鉴会书写区域文旅融合新篇
-
电影《一秒》定档:2026年,活在这一秒
-
西藏斜视患儿寒假进京手术成功,千里护航点亮视觉未来
-
年度盛典|卓兴半导体2025年度总结表彰暨 2026 年迎新晚会
